MA45051A - RELAXIN-CODING POLYNUCLEOTIDES - Google Patents

RELAXIN-CODING POLYNUCLEOTIDES

Info

Publication number
MA45051A
MA45051A MA045051A MA45051A MA45051A MA 45051 A MA45051 A MA 45051A MA 045051 A MA045051 A MA 045051A MA 45051 A MA45051 A MA 45051A MA 45051 A MA45051 A MA 45051A
Authority
MA
Morocco
Prior art keywords
relaxin
coding polynucleotides
polynucleotides
coding
Prior art date
Application number
MA045051A
Other languages
French (fr)
Inventor
Kerry Benenato
Nadege Briancon-Eris
Picciotto Seymour De
Athanasios Dousis
Stephen Hoge
Ellalahewage Sathyajith Kumarasinghe
Iain Mcfadyen
Vladimir Presnyak
Barry Ticho
Zhinan Xia
Original Assignee
Modernatx Inc
Zhinan Xia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc, Zhinan Xia filed Critical Modernatx Inc
Publication of MA45051A publication Critical patent/MA45051A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
MA045051A 2016-05-18 2017-05-18 RELAXIN-CODING POLYNUCLEOTIDES MA45051A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662338470P 2016-05-18 2016-05-18

Publications (1)

Publication Number Publication Date
MA45051A true MA45051A (en) 2019-03-27

Family

ID=60326232

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045051A MA45051A (en) 2016-05-18 2017-05-18 RELAXIN-CODING POLYNUCLEOTIDES

Country Status (12)

Country Link
US (2) US10730924B2 (en)
EP (1) EP3458034A4 (en)
JP (2) JP7088911B2 (en)
KR (2) KR102533456B1 (en)
CN (2) CN115837014A (en)
AU (1) AU2017268394A1 (en)
BR (1) BR112018073683A2 (en)
CA (1) CA3024500A1 (en)
IL (1) IL263079B1 (en)
MA (1) MA45051A (en)
SG (1) SG11201810256XA (en)
WO (1) WO2017201340A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor
RU2021109685A (en) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. VACCINES BASED ON NUCLEIC ACIDS
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
PL3718565T3 (en) 2015-10-22 2022-09-19 Modernatx, Inc. Respiratory virus vaccines
CN117731769A (en) 2015-10-22 2024-03-22 摩登纳特斯有限公司 Nucleic acid vaccine for Varicella Zoster Virus (VZV)
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
DK3386484T3 (en) 2015-12-10 2022-07-04 Modernatx Inc COMPOSITIONS AND METHODS OF DELIVERING THERAPY PRODUCTS
DK3394030T3 (en) 2015-12-22 2022-03-28 Modernatx Inc COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR RELEASE OF FUNDS
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
JP7088911B2 (en) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド Polynucleotide encoding relaxin
AU2017326423B2 (en) 2016-09-14 2023-11-09 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
MA46584A (en) 2016-10-21 2019-08-28 Modernatx Inc HUMAN CYTOMEGALOVIRUS VACCINE
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
MA46766A (en) 2016-11-11 2019-09-18 Modernatx Inc INFLUENZA VACCINE
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. High potency immunogenic compositions
HUE060693T2 (en) 2017-03-15 2023-04-28 Modernatx Inc Compound and compositions for intracellular delivery of therapeutic agents
MA47787A (en) 2017-03-15 2020-01-22 Modernatx Inc RESPIRATORY SYNCYTIAL VIRUS VACCINE
EP3609534A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Broad spectrum influenza virus vaccine
JP7220154B2 (en) 2017-03-15 2023-02-09 モデルナティエックス インコーポレイテッド Crystalline forms of amino lipids
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
CA3055653A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
MA47790A (en) 2017-03-17 2021-05-05 Modernatx Inc RNA-BASED VACCINES AGAINST ZOONOTIC DISEASES
MA48047A (en) * 2017-04-05 2020-02-12 Modernatx Inc REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
KR20200028395A (en) * 2017-06-15 2020-03-16 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Nanostructured lipid carriers and stable emulsions and their use
US11912982B2 (en) 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
MA49914A (en) 2017-08-18 2021-04-21 Modernatx Inc HPLC ANALYTICAL PROCESSES
EP3668971B1 (en) 2017-08-18 2024-04-10 ModernaTX, Inc. Rna polymerase variants
JP7275111B2 (en) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド Method for producing lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. Zika virus rna vaccines
MA54676A (en) 2018-01-29 2021-11-17 Modernatx Inc RSV RNA VACCINES
WO2019236673A1 (en) 2018-06-06 2019-12-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
AU2020224103A1 (en) 2019-02-20 2021-09-16 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
IL288284B1 (en) 2019-05-22 2024-02-01 Massachusetts Inst Technology Circular rna compositions and methods
TW202120536A (en) 2019-07-31 2021-06-01 美商美國禮來大藥廠 Relaxin analogs and methods of using the same
CA3154618A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
ES2961245T3 (en) 2019-12-04 2024-03-11 Orna Therapeutics Inc Circular RNA compositions and methods
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine
US20230174610A1 (en) * 2020-05-08 2023-06-08 President And Fellows Of Harvard College Engineered relaxins and methods of use thereof
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20220090201A1 (en) * 2020-09-04 2022-03-24 University Of Kentucky Research Foundation Clinical assessment of cerebral vasospasm risk following aneurysmal subarachnoid hemorrhage
JP6860739B1 (en) * 2020-11-20 2021-04-21 ジェイ−ネットワーク，インコーポレイテッド Antioxidant expression enhancer in the epidermis
MX2021012823A (en) * 2020-11-27 2022-11-08 Guangzhou Ribobio Co Ltd Lipid compound and the composition thereof.
WO2022112855A1 (en) * 2020-11-27 2022-06-02 Guangzhou Ribobio Co., Ltd Lipid compound and the composition thereof
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CN113264842B (en) 2021-07-21 2022-03-01 苏州科锐迈德生物医药科技有限公司 Lipid compound, lipid carrier containing same, nucleic acid lipid nanoparticle composition and pharmaceutical preparation
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
WO2023056044A1 (en) * 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023222081A1 (en) * 2022-05-19 2023-11-23 仁景(苏州)生物科技有限公司 Long-chain alkyl ester amine lipid compound, preparation method therefor, and use thereof in nucleic acid delivery
CN115521220B (en) * 2022-05-19 2023-06-09 仁景(苏州)生物科技有限公司 Long-chain alkyl ester amine compound, preparation method thereof and application thereof in nucleic acid delivery
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN115389756B (en) * 2022-10-24 2023-02-17 首都医科大学附属北京安贞医院 Detection kit for predicting risk of atrial fibrillation and application thereof

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69469A (en) 1982-08-12 1991-06-10 Florey Howard Inst Polypeptide having human h1-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
US5320953A (en) 1982-08-12 1994-06-14 Howard Florey Institute Of Experimental Physiology And Medicine Process for synthesizing human H1-prorelaxin, H1-relaxin and fusion proteins thereof
US5053488A (en) 1982-08-12 1991-10-01 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a gene sequence coding for human relaxin
US5145962A (en) 1982-08-12 1992-09-08 Howard Florey Institute Of Experimental Physiology And Medicine Human pro relaxin polypeptides
NZ206534A (en) 1982-12-13 1988-05-30 Florey Howard Inst Molecular cloning and characterisation of gene sequence coding for human relaxin
US5179195A (en) 1982-12-13 1993-01-12 Howard Florey Institute Of Experimental Physiology And Medicine Human relaxin polypeptides
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
EP0204401A1 (en) 1985-04-09 1986-12-10 Biogen, Inc. Method of improving the yield of polypeptides produced in a host cell by stabilizing mRNA
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
ATE260340T1 (en) * 1995-11-03 2004-03-15 Regeneron Pharma MOLECULAR CLONING AND CHARACTERIZATION OF MOLECULES RELATED TO RELAXIN AND LIGANDS OF THE INSULIN FAMILY
EP1021549A2 (en) 1997-09-19 2000-07-26 Sequitur, Inc. SENSE mRNA THERAPY
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
EP1800697B1 (en) 2001-06-05 2010-04-14 CureVac GmbH Stabilised mRNA with increased G/C-content for use in gene therapy
AUPR814401A0 (en) * 2001-10-08 2001-11-01 Howard Florey Institute Of Experimental Physiology And Medicine Human 3 relaxin
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
KR100749857B1 (en) * 2004-03-30 2007-08-16 연세대학교 산학협력단 Gene Delivery System Containing Relaxin Gene and Pharmaceutical Composition Using Relaxin
JP4764426B2 (en) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド Cationic lipids and methods of use
WO2006074341A2 (en) * 2005-01-07 2006-07-13 Glaxo Group Limited Novel use
LT2578685T (en) 2005-08-23 2019-06-10 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
US8603457B2 (en) 2005-12-02 2013-12-10 University Of Rochester Nonsense suppression and genetic codon alteration by targeted modification
ES2374458T3 (en) 2006-01-13 2012-02-16 The Trustees Of The University Of Pennsylvania IMMUNOTHERAPEUTIC VACCINES AND AGENTS USING OPTIMIZED IL-15 IN CODONS, AND METHODS FOR USING THEMSELVES.
MX363224B (en) 2006-10-03 2019-03-15 Alnylam Pharmaceuticals Inc Lipid containing formulations.
DE102006051516A1 (en) 2006-10-31 2008-05-08 Curevac Gmbh (Base) modified RNA to increase the expression of a protein
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
WO2009039198A2 (en) 2007-09-17 2009-03-26 The Trustees Of The University Of Pennsylvania Generation of hyperstable mrnas
ES2638448T3 (en) 2008-04-15 2017-10-20 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid administration
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
CA3006395C (en) 2008-11-07 2022-05-31 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
KR20210158864A (en) 2008-11-10 2021-12-31 알닐람 파마슈티칼스 인코포레이티드 Novel lipids and compositions for the delivery of therapeutics
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CN102405232B (en) 2009-02-19 2015-08-19 葛兰素集团有限公司 The anti-serum albumin binding variants of improvement
KR101819754B1 (en) 2009-02-19 2018-01-18 글락소 그룹 리미티드 Improved anti-serum albumin binding variants
PT3431076T (en) 2009-06-10 2021-10-26 Arbutus Biopharma Corp Improved lipid formulation
US8353800B2 (en) 2009-06-12 2013-01-15 Eaton Corporation Limited slip differential using face gears and a pinion housing
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
ES2605625T3 (en) 2009-07-27 2017-03-15 Auspex Pharmaceuticals, Inc. P2Y12 receptor cyclopropyl modulators
US8389475B2 (en) 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
CA2816925C (en) * 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
RS57314B1 (en) 2009-12-01 2018-08-31 Translate Bio Inc Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
EP3112467B1 (en) 2009-12-07 2018-02-14 The Trustees of the University of Pennsylvania Rna preparations comprising purified modified rna for reprogramming cells
ES2749426T3 (en) 2009-12-18 2020-03-20 Univ British Columbia Nucleic Acid Administration Methods and Compositions
US20110200582A1 (en) 2009-12-23 2011-08-18 Novartis Ag Lipids, lipid compositions, and methods of using them
US20110243942A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Relaxin-fusion proteins with extended in vivo half-lives
US8802438B2 (en) 2010-04-16 2014-08-12 Children's Medical Center Corporation Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
JP5957646B2 (en) 2010-06-04 2016-07-27 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Novel low molecular weight cationic lipids for oligonucleotide delivery
PL2590626T3 (en) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomes with lipids having an advantageous pka-value for rna delivery
CN108042799A (en) 2010-07-06 2018-05-18 诺华股份有限公司 cationic oil-in-water emulsion
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
SI3243526T1 (en) 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. Delivery of rna to trigger multiple immune pathways
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
MA34521B1 (en) 2010-08-17 2013-09-02 Ambrx Inc MODIFIED RELAXINE POLYPEPTIDES AND USES THEREOF
WO2012031046A2 (en) 2010-08-31 2012-03-08 Novartis Ag Lipids suitable for liposomal delivery of protein-coding rna
SI4008357T1 (en) 2010-08-31 2023-04-28 Glaxosmithkline Biologicals Sa Small liposomes for delivery of immunogen-encoding rna
HRP20230185T8 (en) 2010-08-31 2023-07-21 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
EP3144015B1 (en) 2010-09-20 2021-06-02 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
DK2663548T3 (en) 2011-01-11 2017-07-24 Alnylam Pharmaceuticals Inc PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
DE12722942T1 (en) 2011-03-31 2021-09-30 Modernatx, Inc. RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
EP3460064B8 (en) 2011-04-03 2024-03-20 The General Hospital Corporation d/b/a Massachusetts General Hospital Efficient protein expression in vivo using modified rna (mod-rna)
CA2835428A1 (en) 2011-05-17 2012-11-22 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof for non-human vertebrates
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
JP6184945B2 (en) 2011-06-08 2017-08-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Lipid nanoparticle compositions and methods for mRNA delivery
KR20140054009A (en) * 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 Relaxin fusion polypeptides and uses thereof
MX2014000316A (en) 2011-07-08 2014-02-19 Bayer Ip Gmbh Fusion proteins releasing relaxin and uses thereof.
BR112014004607A2 (en) 2011-08-31 2017-03-21 Novartis Ag pegylated liposomes for immunogenic encoded RNA delivery
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
EP2755693A4 (en) 2011-09-12 2015-05-20 Moderna Therapeutics Inc Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (en) 2011-10-03 2022-04-07 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DK2768958T3 (en) 2011-10-18 2019-09-16 Dicerna Pharmaceuticals Inc CATIONIC AMINLIPIDS AND APPLICATIONS THEREOF
CN113149869A (en) 2011-10-27 2021-07-23 麻省理工学院 Amino acid derivatives functionalized at the N-terminus capable of forming drug-encapsulated microspheres
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
US20140378538A1 (en) 2011-12-14 2014-12-25 Moderma Therapeutics, Inc. Methods of responding to a biothreat
WO2013090186A1 (en) 2011-12-14 2013-06-20 modeRNA Therapeutics Modified nucleic acids, and acute care uses thereof
US9636414B2 (en) 2011-12-15 2017-05-02 Biontech Ag Particles comprising single stranded RNA and double stranded RNA for immunomodulation
LT2791160T (en) 2011-12-16 2022-06-10 Modernatx, Inc. Modified mrna compositions
WO2013090601A2 (en) 2011-12-16 2013-06-20 Massachusetts Institute Of Technology Compact nanoparticles for biological applications
US10322089B2 (en) 2012-03-14 2019-06-18 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles, nanoparticle delivery methods, and systems of delivery
AU2013231638B2 (en) 2012-03-16 2017-10-12 Merck Patent Gmbh Targeting aminoacid lipids
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
CN108949772A (en) * 2012-04-02 2018-12-07 现代泰克斯公司 For generating the modification polynucleotides of biological agent relevant to human diseases and protein
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US10245229B2 (en) * 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
US20150307542A1 (en) 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PL2922554T3 (en) 2012-11-26 2022-06-20 Modernatx, Inc. Terminally modified rna
EP3628335B1 (en) * 2012-12-07 2023-11-08 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery in the lungs
EP2931914A4 (en) 2012-12-13 2016-08-17 Moderna Therapeutics Inc Modified polynucleotides for altering cell phenotype
AR094147A1 (en) 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft FUSION POLIPEPTIDES WITH RELAXIN ACTIVITY AND ITS USES
WO2014110368A1 (en) * 2013-01-11 2014-07-17 The California Institute For Biomedical Research Bovine fusion antibodies
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3431592A1 (en) * 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
CN105209490A (en) 2013-03-14 2015-12-30 夏尔人类遗传性治疗公司 Methods and compositions for delivering mRNA coded antibodies
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
EP3693397A1 (en) 2013-07-11 2020-08-12 The Scripps Research Institute Coiled coil immunoglobulin fusion proteins and compositions thereof
EA037503B1 (en) * 2014-01-21 2021-04-05 Анджариум Байосайенсиз Аг Process for manufacturing a hybridosome, hybridosome manufactureed by the process and method for delivering a therapeutic or diagnostic agent
WO2015157829A1 (en) 2014-04-17 2015-10-22 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
RU2021109685A (en) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. VACCINES BASED ON NUCLEIC ACIDS
US10975391B2 (en) 2014-04-25 2021-04-13 University Of Massachusetts Recombinant AAV vectors useful for reducing immunity against transgene products
CN106661128A (en) * 2014-06-06 2017-05-10 加州生物医学研究所 Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
CA3179824A1 (en) * 2014-06-25 2015-12-30 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN114642735A (en) 2015-01-21 2022-06-21 菲泽尔克斯公司 Methods, compositions and systems for delivering therapeutic and diagnostic agents into cells
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
EP3307305A4 (en) 2015-06-10 2019-05-22 Modernatx, Inc. Targeted adaptive vaccines
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017019935A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Multimeric mrna
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017031241A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Rna mapping/fingerprinting
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US10849920B2 (en) 2015-10-05 2020-12-01 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
CN117731769A (en) 2015-10-22 2024-03-22 摩登纳特斯有限公司 Nucleic acid vaccine for Varicella Zoster Virus (VZV)
WO2017070618A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
CN108472355A (en) 2015-10-22 2018-08-31 摩登纳特斯有限公司 HSV vaccine
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
KR20180096591A (en) 2015-10-22 2018-08-29 모더나티엑스, 인크. A broad-spectrum influenza virus vaccine
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
JP2019501208A (en) 2015-10-22 2019-01-17 モデルナティーエックス， インコーポレイテッド Respiratory syncytial virus vaccine
PL3718565T3 (en) 2015-10-22 2022-09-19 Modernatx, Inc. Respiratory virus vaccines
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
DK3386484T3 (en) 2015-12-10 2022-07-04 Modernatx Inc COMPOSITIONS AND METHODS OF DELIVERING THERAPY PRODUCTS
US20190275170A1 (en) 2016-05-18 2019-09-12 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
MA45053A (en) 2016-05-18 2019-03-27 Modernatx Inc POLYNUCLEOTIDES CODING FOR A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
JP7088911B2 (en) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド Polynucleotide encoding relaxin
AU2017326423B2 (en) 2016-09-14 2023-11-09 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
MA46584A (en) 2016-10-21 2019-08-28 Modernatx Inc HUMAN CYTOMEGALOVIRUS VACCINE
MA46643A (en) 2016-10-26 2019-09-04 Modernatx Inc METHODS AND COMPOSITIONS FOR RNA MAPPING
JP2019532657A (en) 2016-10-26 2019-11-14 モデルナティーエックス， インコーポレイテッド Messenger ribonucleic acid for enhancing immune response and method of use thereof
MA46766A (en) 2016-11-11 2019-09-18 Modernatx Inc INFLUENZA VACCINE
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
MA47438A (en) 2017-02-01 2019-12-11 Modernatx Inc SECONDARY POLYNUCLEOTIDE STRUCTURE
CN110505877A (en) 2017-02-01 2019-11-26 摩登纳特斯有限公司 RNA cancer vaccine
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. High potency immunogenic compositions
MA47787A (en) 2017-03-15 2020-01-22 Modernatx Inc RESPIRATORY SYNCYTIAL VIRUS VACCINE
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
EP3609534A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Broad spectrum influenza virus vaccine
MA47790A (en) 2017-03-17 2021-05-05 Modernatx Inc RNA-BASED VACCINES AGAINST ZOONOTIC DISEASES

Also Published As

Publication number Publication date
CN109640962B (en) 2022-07-19
IL263079B1 (en) 2024-01-01
RU2018142589A (en) 2020-06-18
JP2019516409A (en) 2019-06-20
US10730924B2 (en) 2020-08-04
WO2017201340A2 (en) 2017-11-23
US20180371047A1 (en) 2018-12-27
KR20190026670A (en) 2019-03-13
AU2017268394A1 (en) 2019-01-03
EP3458034A2 (en) 2019-03-27
JP7459172B2 (en) 2024-04-01
SG11201810256XA (en) 2018-12-28
EP3458034A4 (en) 2020-01-01
JP2022124489A (en) 2022-08-25
CN115837014A (en) 2023-03-24
US20200354429A1 (en) 2020-11-12
KR102533456B1 (en) 2023-05-17
CA3024500A1 (en) 2017-11-23
RU2018142589A3 (en) 2020-09-18
BR112018073683A2 (en) 2019-02-26
JP7088911B2 (en) 2022-06-21
CN109640962A (en) 2019-04-16
IL263079A (en) 2018-12-31
KR20230074598A (en) 2023-05-30
WO2017201340A3 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
MA45051A (en) RELAXIN-CODING POLYNUCLEOTIDES
DK3405050T3 (en) CHILD-PROTECTED SNUCKER
DK3436823T3 (en) ANTIGEN-ARRAY
FI20160137A (en) Felströmindikator
DK3445708T3 (en) STIRBØJLE
DK3402792T3 (en) QUINOLIN-2-ON DERIVATORS
DK3335532T3 (en) Tandsharve
DK3509963T3 (en) PALLECONTAINER
FI20165213A (en) Hyperspektrikuvausjärjestely
FI20165164A (en) floatplane
DK3528829T3 (en) BACITRACIN-ALGINATE-OLIGOMER-CONJUGATES
DK3575238T3 (en) PALLECONTAINER
FI20165299A (en) HENKILÖNOSTIN
DE112017006386A5 (en) Schraubarbeitszylinder
DE112017000734A5 (en) Glycolsensor
DK3471535T3 (en) DYRELIFT
DK3323708T3 (en) BOVFENDER
DK3452590T3 (en) PLADEMAGNET
DK3452587T3 (en) PENICILLIN-G-ACYLASER
DK3295800T3 (en) SANDWICHKIKSINDRETNING
DE112017006474A5 (en) Gargerätevorrichtung
DK3551954T3 (en) RECOPERATOR
DE112017005767A5 (en) NASSLAUFENEN LAMELLENKUPPLUNG
DK3468607T3 (en) RESVERATROLSOLUBILISAT
DK3430609T3 (en) SMARTFLAG